NasdaqCM:CASI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$163.6m

Last Updated

2021/07/28 02:09 UTC

Data Sources

Company Financials +

Executive Summary

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. More Details


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has CASI Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CASI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: CASI's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-10.0%

CASI

-1.5%

US Biotechs

0.9%

US Market


1 Year Return

-41.2%

CASI

19.1%

US Biotechs

37.8%

US Market

Return vs Industry: CASI underperformed the US Biotechs industry which returned 19.1% over the past year.

Return vs Market: CASI underperformed the US Market which returned 37.8% over the past year.


Shareholder returns

CASIIndustryMarket
7 Day-10.0%-1.5%0.9%
30 Day-27.8%-1.3%0.3%
90 Day-39.4%0.2%2.1%
1 Year-41.2%-41.2%20.8%19.1%40.0%37.8%
3 Year-84.0%-84.0%23.4%17.4%63.8%53.5%
5 Year0%0%43.7%32.2%124.6%99.7%

Long-Term Price Volatility Vs. Market

How volatile is CASI Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CASI Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CASI ($1.17) is trading below our estimate of fair value ($9.56)

Significantly Below Fair Value: CASI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CASI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CASI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CASI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CASI is good value based on its PB Ratio (1.6x) compared to the US Biotechs industry average (2.8x).


Future Growth

How is CASI Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

57.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CASI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CASI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CASI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CASI's revenue (55.9% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: CASI's revenue (55.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CASI's Return on Equity is forecast to be high in 3 years time


Past Performance

How has CASI Pharmaceuticals performed over the past 5 years?

-40.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CASI is currently unprofitable.

Growing Profit Margin: CASI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CASI is unprofitable, and losses have increased over the past 5 years at a rate of 40.5% per year.

Accelerating Growth: Unable to compare CASI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CASI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).


Return on Equity

High ROE: CASI has a negative Return on Equity (-43.34%), as it is currently unprofitable.


Financial Health

How is CASI Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CASI's short term assets ($89.0M) exceed its short term liabilities ($10.0M).

Long Term Liabilities: CASI's short term assets ($89.0M) exceed its long term liabilities ($15.9M).


Debt to Equity History and Analysis

Debt Level: CASI's debt to equity ratio (1.6%) is considered satisfactory.

Reducing Debt: CASI's debt to equity ratio has reduced from 31.3% to 1.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CASI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CASI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is CASI Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CASI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CASI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CASI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CASI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CASI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Wei-Wu He (56 yo)

2.25yrs

Tenure

US$819,487

Compensation

Dr. Wei-Wu He, Ph.D. is Chairman Emeritus at Genetron Holdings Limited since June 30, 2021 and served as its Chairman since May 2015 until June 30, 2021. He serves as Chairman and Chief Executive Officer a...


CEO Compensation Analysis

Compensation vs Market: Wei-Wu's total compensation ($USD819.49K) is about average for companies of similar size in the US market ($USD1.11M).

Compensation vs Earnings: Wei-Wu's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CASI's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: CASI's board of directors are considered experienced (7.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.8%.


Top Shareholders

Company Information

CASI Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CASI Pharmaceuticals, Inc.
  • Ticker: CASI
  • Exchange: NasdaqCM
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$163.563m
  • Shares outstanding: 139.80m
  • Website: https://www.casipharmaceuticals.com

Number of Employees


Location

  • CASI Pharmaceuticals, Inc.
  • 9620 Medical Center Drive
  • Suite 300
  • Rockville
  • Maryland
  • 20850
  • United States

Listings


Biography

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, a...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/28 02:09
End of Day Share Price2021/07/27 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.